AIMT
Aimmune Therapeutics
AIMT
AIMT
Delisted
AIMT was delisted on the 12th of October, 2020.
125 hedge funds and large institutions have $1.02B invested in Aimmune Therapeutics in 2019 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 49 increasing their positions, 28 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4% less capital invested
Capital invested by funds: $1.07B → $1.02B (-$45.5M)
Holders
125
Holding in Top 10
4
Calls
$5.91M
Puts
$4.29M
Top Buyers
| 1 | +$16.9M | |
| 2 | +$11.1M | |
| 3 | +$10.8M | |
| 4 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$5.44M |
| 5 |
Nuveen Asset Management
Chicago,
Illinois
|
+$3.97M |
Top Sellers
| 1 | -$17.9M | |
| 2 | -$8.94M | |
| 3 | -$6.72M | |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$6.06M |
| 5 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$4.08M |